Barclays PLC Cti Biopharma Corp Transaction History

Barclays PLC

  • $327 Billion
  • Q2 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023
SELL
$4.2 - $6.01 $929,720 - $1.33 Million
-221,362 Reduced 29.19%
536,999 $2.26 Million
Q4 2022

Feb 13, 2023
BUY
$4.45 - $6.17 $354,878 - $492,045
79,748 Added 11.75%
758,361 $4.56 Million
Q3 2022

Nov 03, 2022
BUY
$5.36 - $7.43 $3.61 Million - $5.01 Million
673,949 Added 14450.02%
678,613 $3.95 Million
Q2 2022

Aug 12, 2022
BUY
$3.55 - $6.27 $16,500 - $29,142
4,648 Added 29050.0%
4,664 $28,000
Q1 2022

May 16, 2022
SELL
$1.9 - $5.23 $950 - $2,615
-500 Reduced 96.9%
16 $0
Q4 2021

Feb 14, 2022
SELL
$1.44 - $2.86 $36,852 - $73,193
-25,592 Reduced 98.02%
516 $1,000
Q3 2021

Nov 09, 2021
BUY
$2.25 - $3.18 $46,131 - $65,199
20,503 Added 365.8%
26,108 $77,000
Q2 2021

Aug 13, 2021
SELL
$2.16 - $2.62 $128,193 - $155,494
-59,349 Reduced 91.37%
5,605 $14,000
Q1 2021

May 13, 2021
BUY
$2.68 - $3.8 $172,691 - $244,860
64,437 Added 12463.64%
64,954 $190,000
Q3 2020

Nov 12, 2020
SELL
$1.02 - $2.15 $897 - $1,892
-880 Reduced 62.99%
517 $1,000
Q2 2020

Aug 12, 2020
BUY
$0.88 - $1.32 $774 - $1,161
880 Added 170.21%
1,397 $2,000
Q3 2019

Nov 14, 2019
SELL
$0.64 - $0.92 $313 - $450
-490 Reduced 48.66%
517 $0
Q2 2019

Aug 14, 2019
SELL
$0.8 - $1.03 $11,158 - $14,366
-13,948 Reduced 93.27%
1,007 $0
Q1 2019

May 15, 2019
BUY
$0.9 - $1.37 $12,994 - $19,780
14,438 Added 2792.65%
14,955 $15,000
Q4 2018

Feb 14, 2019
SELL
$0.73 - $2.19 $16,970 - $50,910
-23,247 Reduced 97.82%
517 $0
Q3 2018

Nov 14, 2018
SELL
$1.72 - $5.24 $25,638 - $78,107
-14,906 Reduced 38.55%
23,764 $51,000
Q2 2018

Aug 14, 2018
SELL
$3.81 - $5.26 $40,591 - $56,040
-10,654 Reduced 21.6%
38,670 $193,000
Q1 2018

May 15, 2018
BUY
$2.7 - $4.06 $131,765 - $198,136
48,802 Added 9349.04%
49,324 $192,000
Q3 2017

Nov 14, 2017
BUY
$3.12 - $3.65 $1,628 - $1,905
522
522 $2,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email